A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 794 participants.

Also called NCT05433584

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 794 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05433584
  • EudraCT 2022-000130-42
  • WHO UTN U1111-1282-0263
Other papers using this trial's data
  • Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial Annals of internal medicine, 2026-07 DOI, PubMed 42184419

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Canada, Germany, Israel, Italy, Mexico, Puerto Rico, Romania, Slovakia, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05433584. Randomized; no masking; primary purpose treatment. Start 2022-08-01 (actual); primary completion 2025-10-21 (actual). Results posted on 2026-11-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Acronym
SURPASS-EARLY
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Antihyperglycemic medication
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05433584
Content hash
b99573e9257379e5bc4b1d3a1213205b2ba61b5a137de65fdf5a66927e13639e